Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-866: Perioperative Pembrolizumab + Chemotherapy in Muscle-invasive Bladder Cancer
NCT03924856Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2019
- Primary completion
- Jan 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial in muscle-invasive bladder cancer (MIBC) comparing Pembrolizumab + Gemcitabine + Cisplatin + Surgery with Placebo + Gemcitabine + Cisplatin + Surgery (2 arms). Primary endpoint: Event-Free Survival at 60 months. Started Jun 2019; status: completed.
02
Drugs
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT03924856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03924856.